Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | IDO1 | P14902 | 3/20 | 0.38 |
| ▸ | JAK2 | O60674 | 5/20 | 0.36 |
| ▸ | JAK1 | P23458 | 5/20 | 0.36 |
| ▸ | TYK2 | P29597 | 5/20 | 0.36 |
| ▸ | JAK3 | P52333 | 5/20 | 0.36 |
| ▸ | NOS1 | P29475 | 3/20 | 0.36 |
| ▸ | AXL | P30530 | 2/20 | 0.36 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.36 |
| ▸ | P4HB | P07237 | 2/20 | 0.35 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.35 |
| ▸ | CDK2 | P24941 | 1/20 | 0.35 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.35 |
| ▸ | METAP2 | P50579 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5408184 | 0.83 | IDO1 (0.40) | IDO1JAK2JAK1TYK2JAK3 | |
| SCHEMBL5401942 | 0.76 | CDK2 (0.40) | IDO1JAK2JAK1TYK2JAK3 | |
| SCHEMBL5404343 | 0.73 | FGFR1 (0.44) | IDO1JAK2JAK1TYK2JAK3 | |
| SCHEMBL21437262 | 0.72 | NOS1 (0.44) | IDO1NOS1AXLFGFR1P4HB | |
| SCHEMBL5410281 | 0.70 | BRD4 (0.36) | IDO1JAK2JAK1TYK2JAK3 | |
| SCHEMBL5412653 | 0.69 | NOS1 (0.50) | IDO1JAK2JAK1TYK2JAK3 | |
| SCHEMBL31740241 | 0.69 | TRPA1 (0.47) | IDO1JAK2JAK1TYK2JAK3 | |
| SCHEMBL5421701 | 0.69 | TRPA1 (0.47) | IDO1JAK2JAK1TYK2JAK3 | |
| SCHEMBL5413400 | 0.69 | NOS1 (0.50) | IDO1NOS1AXLFGFR1P4HB | |
| SCHEMBL5412686 | 0.69 | BRD4 (0.47) | IDO1JAK2JAK1TYK2JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7199147-B2 | Rho kinase inhibitors | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2007-04-03 | — | — | US | disclosed |
| US-20040138286-A1 | Rho kinase inhibitors | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2004-07-15 | — | — | US | disclosed |
| EP-1403255-A1 | Rho KINASE INHIBITORS | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2004-03-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138286-A1 | Rho kinase inhibitors | ROCK1, ROCK2, ARHGDIA | SMN1; SMN2 3394/4885IDO1 2940/4885JAK2 929/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.